Project Grant K23HL179316
Award Date
7/15/25
Completion Date
6/30/30
Dollars Obligated
$173K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of reduced hypusination of the translation factor EIF5A in the development of heart failure with preserved ejection fraction (HFpEF). The $126,387 award to The Johns Hopkins University, granted on June 15, 2025, aims to study how depressed EIF5A hypusination impairs the translation of ubiquitin precursors and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $735,838 to the University of Arizona to conduct research on the role of hexokinase 1 (HK1) mitochondrial binding in cardiac endothelial cell function and the development of heart failure with preserved ejection fraction (HFpEF). The research aims to determine if HK1 mitochondrial dislocation leads to increased protein O-GlcNAcylation,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $869,696 to Vanderbilt University Medical Center to investigate the relationship between preeclampsia during pregnancy and the development of heart failure with preserved ejection fraction (HFpEF) in women. The key objectives are to: 1) measure the relationship between post-partum subclinical left ventricular diastolic dysfunction and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support an investigation into the role of resistance exercise in the prevention and treatment of heart failure with preserved ejection fraction (HFpEF). The $117,789 award, with a period of performance from September 9, 2024 to August 31, 2026, will fund a research project led by Dr. McDonough at the University of Minnesota. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $777,258 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research focused on unraveling the mechanisms of heart failure in hypertrophic cardiomyopathy. The 5-year project aims to improve understanding of heart failure in hypertrophic cardiomyopathy through novel cardiac magnetic resonance imaging (CMR) phenotyping techniques,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,624 to Vanderbilt University Medical Center to conduct research on hypoxia-inducible factor (HIF)-driven modulation of alveolar regeneration. The research aims to investigate how HIF activation impacts cellular fate and epigenetic programs during alveolar repair, as well as the metabolic processes underlying HIF suppression...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research into the regulation of the autophagy pathway and its relationship to cardiomyopathy and heart failure. The $2,185,454 award to Tufts Medical Center Parent, Inc. will fund a 4-year study investigating the mechanistic basis of a genetic variant (FHOD3V1151I) associated with hypertrophic cardiomyopathy. Key objectives...